Intensity Therapeutics completed a registered direct offering of 5 million shares of common stock at $0.80 per share, raising gross proceeds of approximately $4 million.
The offering, conducted under an effective Form S‑3 registration statement, is expected to close on or about November 3 2025. A.G.P./Alliance Global Partners served as the sole placement agent.
Net proceeds will be used to advance the company’s lead candidate INT230‑6 through Phase 3 soft‑tissue sarcoma and Phase 2 triple‑negative breast cancer trials, support working capital, and fund general corporate purposes. The financing extends the company’s cash runway to the end of the first quarter of 2027.
The offering follows a July 2025 ATM offering that added $6.6 million. Intensity recently regained compliance with Nasdaq’s minimum stockholders’ equity requirement and maintains a low debt‑to‑equity ratio of 0.06, underscoring a strong balance sheet.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.